Quantum BioPharma issued a total of 35,000 stock options to employees and consultants as part of its incentive program aimed at retaining and rewarding key contributors to the company’s growth. Each option vests immediately, is exercisable at CA$6.50 per share for a five-year term, and is subject to a statutory four-month and one-day hold period, in accordance with the stock option plan re-approved on May 19, 2023. These option grants may dilute existing shareholders but align management objectives with long-term value creation as Quantum advances its Lucid-MS candidate for neurodegenerative disorders and maintains a 19.84% stake in Unbuzzd Wellness Inc., with tiered royalties of 7% until $250 million and 3% thereafter.